RSV vaccine sales for elderly to top $10B by 2030 in G7 (NYSE:PFE)


Respiratory syncytial virus vaccine

Hailshadow/iStock via Getty Images

Ahead of the world’s first immunization drive against respiratory syncytial virus (RSV), a new report from the London-based health analytics firm Airfinity suggests RSV vaccine sales for older adults could exceed $10B by 2030 in G7 countries.

For years, RSV was

Source link

Leave A Reply

Your email address will not be published.